CIK 0001528115 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Net income (USD) | -141.9 M | -130.3 M | ||
| Diluted EPS (USD/shares) | -1.34 | -1.77 | -2.6 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-25 | 4 | 4 | 2026-09-24 |
| 2026-08-13 | 144 | 144 | |
| 2026-08-12 | 4 | 4 | 2026-08-10 |
| 2026-08-12 | 3 | 3 | 2026-08-10 |
| 2026-08-12 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-12 | 8-K | 8-K items 2.02,8.01,9.01 | 2026-08-12 |
| 2026-08-10 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-08-10 |
| 2026-08-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-06 | 8-K | 8-K items 8.01,9.01 | 2026-08-06 |
| 2026-07-30 | 8-K | 8-K items 1.01,2.03,8.01,9.01 | 2026-07-30 |
| 2026-07-27 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-15 | 144 | 144 | |
| 2026-07-14 | 144 | 144 | |
| 2026-07-08 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-08 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 8-K | 8-K items 5.07 | 2026-06-11 |
| 2026-05-29 | 4 | 4 | 2026-05-28 |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A |
Forms on file (last 1,000): 4 172, 8-K 74, 144 44, SC 13G/A 37, 3 33, SC 13G 28, 10-Q 19, SCHEDULE 13G/A 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ANNX (0.002 USD), /gw/filings/filings?ticker=ANNX&form=8-K, /gw/filings/facts?ticker=ANNX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange